UCB Cuts $1.15bn Deal to Buy Epilepsy Biotech Neurona

UCB cuts $1.15bn deal to buy epilepsy biotech Neurona

UCB has dipped its toe into the M&A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.

UCB to buy Neurona and NRTX-1001 for $1.15bn

UCB has signed a definitive agreement to acquire Neurona Therapeutics in a deal worth up to $1.15bn, adding the latter’s lead asset NRTX-1001 to its epilepsy portfolio.

UCB spends US$1.15bn on cell therapy biotech for potential regenerative epilepsy therapy - European Biotechnology Magazine

Belgian biopharma UCB has agreed to acquire clinical-stage biotech Neurona Therapeutics for up to US$1.15 billion, betting on a one-off cell therapy that aims to structurally repair the brains of people with drug-resistant epilepsy. The post UCB spends US$1.15bn on cell therapy biotech for potential regenerative epilepsy therapy appeared first on European Biotechnology Magazine.

UCB plots epilepsy expansion with $650M Neurona cell therapy acquisition

UCB plans to pay $650 million for Neurona Therapeutics in a bid to broaden its clinical-stage epilepsy portfolio. The deal comes with as much as $500 million in milestone payments. Neurona is developing a treatment ...